論文・総説​​

​

・Mohri K, Nagai H, Matsuda T, Igarashi Y, Higai K. Second-line Treatment Strategy in Unresectable Hepatocellular Carcinoma After First-line Atezolizumab Plus Bevacizumab. Anticancer Res. 2024 Sep;44(9):3919-3929. doi: 10.21873/anticanres.17220.

 

・Uekusa S, Nemoto M, Hanai Y, Nakashin M, Yanagino S, Arita Y, Matsumoto T, Wakui N, Nagai H, Higai K, Matsuo K. Risk factors for lenvatinib-induced palmar-plantar erythrodysesthesia syndrome in patients with hepatocellular carcinoma: A retrospective study.  Cancer Med. 2024 Aug;13(16):e70065. doi: 10.1002/cam4.70065.

​​

・Nagai H, Mukozu T, Matsui T, Mohri K, Nagumo H, Yoshimine N, Kobayashi K, Ogino Y, Daido Y, Wakui N, Momiyama K, Matsuda T, Igarashi Y, Higai K. Remaining Issues Related to Serum Cytokines in Patients with Unresectable Hepatocellular Carcinoma Treated by Atezolizumab plus Bevacizumab Combination Treatment. Oncology​. 2024  doi: 10.1159/000537965.​

​

・Tatsumi Y, Hayash H, Kato K. Comment to a patient with SLC40A1-HC successfully treated using red blood cell apheresis. Med Mol Morphol. ​2024 Mar;57(1):82. doi: 10.1007/s00795-023-00375-8.

​

・Tatsumi Y, Yano M, Wakusawa S, Miyajima H, Ishikawa T, Imashuku S, Takano A, Nihei W, Kato A, Kato K, Hayashi H, Yoshioka K, Hayashi K. A Revised Classification of Primary Iron Overload Syndromes. 

J Clin Transl Hepatol.​ 2024 Apr 28;12(4):346-356. doi: 10.14218/JCTH.2023.00290.

​

​・Ishikawa T, Tatsumi Y, Kato K, Hayashi Y, Imai N, Ito T, Ishizu Y, Ishigami M, Nihei W, Kato A, Hayashi H. A 70-year-old Woman with Asymptomatic Ferroportin Disease. Intern Med. ​2024 Sep 1;63(17):2421-2425. doi: 10.2169/internalmedicine.2392-23.